JPH0512328B2 - - Google Patents
Info
- Publication number
- JPH0512328B2 JPH0512328B2 JP58220452A JP22045283A JPH0512328B2 JP H0512328 B2 JPH0512328 B2 JP H0512328B2 JP 58220452 A JP58220452 A JP 58220452A JP 22045283 A JP22045283 A JP 22045283A JP H0512328 B2 JPH0512328 B2 JP H0512328B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- sustained
- carrier
- interferon
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002347 injection Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 22
- 238000013268 sustained release Methods 0.000 claims description 13
- 239000012730 sustained-release form Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 235000011803 sesame oil Nutrition 0.000 claims description 8
- 239000008159 sesame oil Substances 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 230000007721 medicinal effect Effects 0.000 claims description 4
- 240000001090 Papaver somniferum Species 0.000 claims description 3
- 235000008753 Papaver somniferum Nutrition 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims 1
- 230000009878 intermolecular interaction Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000312 peanut oil Substances 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 description 16
- 108010050904 Interferons Proteins 0.000 description 16
- 229940079322 interferon Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 239000003405 delayed action preparation Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108010045569 atelocollagen Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- -1 chitin Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012155 injection solvent Substances 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58220452A JPS60112713A (ja) | 1983-11-21 | 1983-11-21 | 有用な徐放性注射剤 |
| DE8484112313T DE3484584D1 (de) | 1983-10-14 | 1984-10-12 | Injektionen mit verzoegerter abgabe. |
| EP19840112313 EP0140255B1 (en) | 1983-10-14 | 1984-10-12 | Sustained-release injections |
| US07/844,929 US5385738A (en) | 1983-10-14 | 1992-03-04 | Sustained-release injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58220452A JPS60112713A (ja) | 1983-11-21 | 1983-11-21 | 有用な徐放性注射剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60112713A JPS60112713A (ja) | 1985-06-19 |
| JPH0512328B2 true JPH0512328B2 (US06376461-20020423-C00021.png) | 1993-02-17 |
Family
ID=16751334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58220452A Granted JPS60112713A (ja) | 1983-10-14 | 1983-11-21 | 有用な徐放性注射剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60112713A (US06376461-20020423-C00021.png) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0657658B2 (ja) * | 1985-04-11 | 1994-08-03 | 住友製薬株式会社 | 徐放性製剤 |
| JPS60174726A (ja) * | 1984-02-21 | 1985-09-09 | Nippon Shinyaku Co Ltd | 注射用医薬組成物 |
| JPH0725688B2 (ja) * | 1986-03-31 | 1995-03-22 | 住友製薬株式会社 | Ｃｓｆ徐放性製剤 |
| JP2609851B2 (ja) * | 1986-09-04 | 1997-05-14 | 悦子 柿崎 | 徐放性注射剤 |
| JPH0725689B2 (ja) * | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
| JP3699141B2 (ja) * | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
| CA2217134A1 (en) * | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835110A (ja) * | 1981-08-28 | 1983-03-01 | Tetsuo Kato | 徐放性マイクロカプセル |
-
1983
- 1983-11-21 JP JP58220452A patent/JPS60112713A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835110A (ja) * | 1981-08-28 | 1983-03-01 | Tetsuo Kato | 徐放性マイクロカプセル |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60112713A (ja) | 1985-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5385738A (en) | Sustained-release injection | |
| KR100356550B1 (ko) | 펩티드의금속염을함유한서방성제제 | |
| KR100236771B1 (ko) | 히아루론산을 이용한 약물의 서방성 미세입자 제형 | |
| EP0946169B1 (en) | Method of producing a sustained-release preparation | |
| EP0633020B1 (en) | Method of producing sustained-release preparation | |
| US5081156A (en) | Sustained-release preparation | |
| US20090142399A1 (en) | Dispersant agent for sustained-release preparations | |
| EP0140255A2 (en) | Sustained-release injections | |
| JP2002533378A (ja) | タンパク質の徐放用ポリオール／油懸濁液 | |
| EP0138216B1 (en) | Sustained-release ifn preparation for parenteral administration | |
| LV10041B (en) | Microcapsules and method of producing thereof | |
| JP4683319B2 (ja) | 徐放性製剤用の分散剤 | |
| JPH0512328B2 (US06376461-20020423-C00021.png) | ||
| JPS62230729A (ja) | Ｃｓｆ徐放性製剤 | |
| JP3862304B2 (ja) | 徐放性製剤 | |
| JPH1045616A (ja) | 注射用徐放性製剤 | |
| JPS60126217A (ja) | 長期徐放性製剤 | |
| WO1989003671A1 (en) | Sustained-release preparation | |
| KR100329336B1 (ko) | 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형 | |
| JPH0372046B2 (US06376461-20020423-C00021.png) | ||
| JPH02710A (ja) | コントロールリリース製剤 | |
| JPH09508118A (ja) | 水性持続放出性処方 | |
| RU2181999C2 (ru) | Препарат с отсроченным высвобождением, способ его получения | |
| JPH05246879A (ja) | 長期徐放性製剤 |
